At Ayass BioScience, we use high-throughput Next Generation Sequencing technology to sequence cancer patients’ solid tumor DNA (Breast cancer, Lung cancer, Colorectal cancer, Prostate cancer, Cervical cancer). Targeted sequencing of tumor DNA across our panel of 26 cancer driving genes can detect tumor biopsy somatic mutations. The results of this test can be useful for assessing prognosis and guiding treatment.